Regular follow-up with your healthcare professional is important to check whether adjustments are needed
Wong, PhD, MPH, a professor of medicine at the University of California, Irvine School of Medicine, and colleagues noted that the impact glucagon-like peptide 1 (GLP-1) receptor agonists have on weight loss have recently generated interest and investigation. Semaglutide activates GLP-1 receptors, improving incretin function and insulin secretion (glucose-dependent), inhibiting glucagon release and suppressing hepatic gluconeogenesis, resulting in reductions in both fasting as well as postprandial glucose, they wrote in Cardiovascular Drugs and Therapy
doi: 10.1038/302716a0 44 DruckerDJMojsovSHabenerJF
However, scientific research on these purported benefits is limited and mixed
By identifying the most frequent pitfalls and taking proactive steps to prevent them, researchers can maintain higher levels of reliability and confidence in their results